Determination of pCrkL level in chronic myeloid leukaemia cells using flow cytometry

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Informatics. Official publication website can be found on muni.cz.
Authors

ŠIMARA Pavel STEJSKAL Stanislav PETERKOVÁ Martina KRONTORÁD KOUTNÁ Irena RÁČIL Zdeněk MAYER Jiří

Year of publication 2010
Type Article in Proceedings
Conference Advances in Molecular and Cancer Biology, 2010
MU Faculty or unit

Faculty of Informatics

Citation
Field Genetics and molecular biology
Keywords CML; imatinib; CD34+; pCrkL; flow cytometry
Description Imatinib is a tyrosine kinase inhibitor nowadays used as a first line therapy for newly diagnosed chronic myeloid leukaemia (CML) patients. However, some of the patients relapse after initially good response. Therefore, reliable methods for predicting of the imatinib treatment response are sought. In our research we determine the level of phosphorylated CrkL protein, known as a substrate of Bcr-Abl, by flow cytometry. Its potential predictive value as a marker of imatinib treatment response will be assessed in the monuclear cells or CD34+ cells of peripheral blood samples of new CML patients.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info